Portfolio Holdings Detail for ISIN IE00BDZVHG35
Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /var/www/liquidata/show_ticker_holding_ETFs.php on line 77
Stock Name / Fund iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer Blackrock

ETF Ticker BTEE(USD) LSE
ETF Ticker BTEE.L(GBP) LSE

Holdings detail for IMVT

Stock Name	Immunovant Inc
Ticker	IMVT(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US45258J1025

Show aggregate IMVT holdings

News associated with IMVT

Immunovant, Inc. (NASDAQ:IMVT) Given Consensus Recommendation of “Moderate Buy” by Brokerages: Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) has received a consensus recommendation of “Moderate Buy” from the twelve ratings firms that are covering the company, Marketbeat Ratings reports. Three research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating on the […] - 2025-08-26 04:26:49
Bank of America Lowers Immunovant (NASDAQ:IMVT) Price Target to $30.00: Immunovant (NASDAQ:IMVT – Get Free Report) had its price objective reduced by equities research analysts at Bank of America from $33.00 to $30.00 in a report released on Tuesday,Benzinga reports. The firm currently has a “buy” rating on the stock. Bank of America‘s price objective would suggest a potential upside of 88.80% from the stock’s […] - 2025-08-14 03:07:05
Immunovant Posts 34% R&D Jump in Q1: Key Points- Immunovant’s net loss widened to $0.71 per share (GAAP) in Q1 FY2026 as expenses rose with pipeline expansion. - 2025-08-11 08:27:59
Immunovant, Inc. (NASDAQ:IMVT) Receives $36.40 Average Price Target from Analysts: Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the eleven ratings firms that are presently covering the stock, Marketbeat.com reports. Three analysts have rated the stock with a hold recommendation, seven have issued a buy recommendation and one has assigned a strong buy recommendation to the […] - 2025-08-04 02:42:53
Analysts Set Immunovant, Inc. (NASDAQ:IMVT) Target Price at $38.33: Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the ten brokerages that are covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company. The […] - 2025-07-10 02:50:51
Immunovant, Inc. (NASDAQ:IMVT) Receives Consensus Rating of “Moderate Buy” from Brokerages: Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) has earned an average recommendation of “Moderate Buy” from the ten analysts that are currently covering the stock, Marketbeat.com reports. Two equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the […] - 2025-06-12 05:18:48
How The Pieces Add Up: SCHK Headed For $32: Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-06-05 07:23:06
ProShare Advisors LLC Buys 3,681 Shares of Immunovant, Inc. (NASDAQ:IMVT): ProShare Advisors LLC boosted its position in Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 18.8% during the 4th quarter, Holdings Channel.com reports. The firm owned 23,300 shares of the company’s stock after purchasing an additional 3,681 shares during the period. ProShare Advisors LLC’s holdings in Immunovant were worth $577,000 as of its most recent filing […] - 2025-05-26 05:18:59
Immunovant, Inc. (NASDAQ:IMVT) Receives Average Recommendation of “Moderate Buy” from Brokerages: Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) has been given a consensus rating of “Moderate Buy” by the ten ratings firms that are covering the firm, Marketbeat reports. Two analysts have rated the stock with a hold recommendation, seven have given a buy recommendation and one has given a strong buy recommendation to the company. […] - 2025-05-23 05:00:51
Immunovant, Inc. (NASDAQ:IMVT) Shares Purchased by D. E. Shaw & Co. Inc.: D. E. Shaw & Co. Inc. increased its holdings in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 8.4% in the fourth quarter, Holdings Channel reports. The firm owned 67,669 shares of the company’s stock after buying an additional 5,234 shares during the quarter. D. E. Shaw & Co. Inc.’s holdings in Immunovant were […] - 2025-05-22 04:48:46
The Manufacturers Life Insurance Company Sells 772 Shares of Immunovant, Inc. (NASDAQ:IMVT): The Manufacturers Life Insurance Company lowered its stake in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 2.1% during the fourth quarter, HoldingsChannel reports. The firm owned 35,908 shares of the company’s stock after selling 772 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Immunovant were worth $889,000 as of its […] - 2025-05-15 04:45:06
Invesco Ltd. Lowers Holdings in Immunovant, Inc. (NASDAQ:IMVT): Invesco Ltd. reduced its position in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 15.2% in the fourth quarter, Holdings Channel reports. The firm owned 504,032 shares of the company’s stock after selling 90,210 shares during the period. Invesco Ltd.’s holdings in Immunovant were worth $12,485,000 at the end of the most recent reporting […] - 2025-04-22 04:57:06
Geode Capital Management LLC Purchases 4,094 Shares of Immunovant, Inc. (NASDAQ:IMVT): Geode Capital Management LLC grew its position in Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 0.3% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,515,020 shares of the company’s stock after acquiring an additional 4,094 shares during the quarter. Geode […] - 2025-04-16 04:39:00
Norges Bank Buys Shares of 637,947 Immunovant, Inc. (NASDAQ:IMVT): Norges Bank purchased a new position in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 637,947 shares of the company’s stock, valued at approximately $15,802,000. A number of other large investors have also […] - 2025-04-08 04:46:59
Peek Under The Hood: DFAC Has 28% Upside: Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-04-04 08:47:40
Teacher Retirement System of Texas Acquires 2,373 Shares of Immunovant, Inc. (NASDAQ:IMVT): Teacher Retirement System of Texas increased its holdings in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 18.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 15,203 shares of the company’s stock after acquiring an additional 2,373 shares during the quarter. […] - 2025-04-01 04:44:44
Brokerages Set Immunovant, Inc. (NASDAQ:IMVT) Price Target at $41.00: Shares of Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) have been given a consensus recommendation of “Buy” by the ten analysts that are covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation, eight have issued a buy recommendation and one has given a strong buy recommendation to the […] - 2025-04-01 02:40:43
HC Wainwright Reiterates “Buy” Rating for Immunovant (NASDAQ:IMVT): Immunovant (NASDAQ:IMVT – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $51.00 price objective on the stock. HC Wainwright’s target price indicates a potential upside of 159.01% from the company’s previous close. Several other […] - 2025-03-21 04:42:50
Guggenheim Reaffirms Buy Rating for Immunovant (NASDAQ:IMVT): Guggenheim reiterated their buy rating on shares of Immunovant (NASDAQ:IMVT – Free Report) in a report issued on Monday morning,Benzinga reports. A number of other brokerages have also issued reports on IMVT. Cantor Fitzgerald upgraded shares of Immunovant to a “strong-buy” rating in a research report on Tuesday, March 4th. Jefferies Financial Group assumed coverage […] - 2025-03-11 04:40:47
Immunovant, Inc. (NASDAQ:IMVT) Receives $43.55 Consensus Target Price from Analysts: Shares of Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) have received an average recommendation of “Moderate Buy” from the thirteen ratings firms that are currently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has issued a strong buy […] - 2025-03-07 04:43:06
Immunovant (NASDAQ:IMVT) Coverage Initiated at Jefferies Financial Group: Equities researchers at Jefferies Financial Group began coverage on shares of Immunovant (NASDAQ:IMVT – Get Free Report) in a research report issued to clients and investors on Monday, MarketBeat.com reports. The brokerage set a “hold” rating and a $20.00 price target on the stock. Jefferies Financial Group’s price objective suggests a potential upside of 8.17% […] - 2025-03-05 05:04:58
Comparing Immunovant (NASDAQ:IMVT) & OKYO Pharma (NASDAQ:OKYO): Immunovant (NASDAQ:IMVT – Get Free Report) and OKYO Pharma (NASDAQ:OKYO – Get Free Report) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, risk, dividends and institutional ownership. Profitability This table compares Immunovant and OKYO Pharma’s net […] - 2025-03-05 04:20:53
Immunovant, Inc. (NASDAQ:IMVT) Shares Sold by Principal Financial Group Inc.: Principal Financial Group Inc. trimmed its holdings in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 16.7% in the 4th quarter, HoldingsChannel.com reports. The fund owned 791,863 shares of the company’s stock after selling 159,261 shares during the quarter. Principal Financial Group Inc.’s holdings in Immunovant were worth $19,614,000 as of its most recent […] - 2025-02-25 06:48:54
Guggenheim Cuts Immunovant (NASDAQ:IMVT) Price Target to $44.00: Immunovant (NASDAQ:IMVT – Get Free Report) had its price target dropped by equities researchers at Guggenheim from $46.00 to $44.00 in a research report issued to clients and investors on Monday,Benzinga reports. The firm presently has a “buy” rating on the stock. Guggenheim’s price objective would indicate a potential upside of 127.51% from the company’s […] - 2025-02-12 06:46:57
Immunovant, Inc. (NASDAQ:IMVT) Receives $47.00 Consensus PT from Brokerages: Shares of Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) have been assigned an average recommendation of “Buy” from the twelve ratings firms that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating […] - 2025-02-12 06:09:06
Immunovant (NASDAQ:IMVT) Sets New 1-Year Low on Disappointing Earnings: Immunovant, Inc. (NASDAQ:IMVT – Get Free Report) shares hit a new 52-week low during trading on Monday following a weaker than expected earnings announcement. The stock traded as low as $19.82 and last traded at $19.60, with a volume of 702620 shares trading hands. The stock had previously closed at $20.41. The company reported ($0.76) […] - 2025-02-12 04:14:58
Immunovant, Inc. (NASDAQ:IMVT) Shares Bought by KBC Group NV: KBC Group NV boosted its position in shares of Immunovant, Inc. (NASDAQ:IMVT – Free Report) by 60.1% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 3,099 shares of the company’s stock after buying an additional 1,163 shares during the quarter. KBC Group NV’s […] - 2025-02-10 16:30:58

iShares Nasdaq US Biotechnology UCITS ETF USD (Dist) IMVT holdings

Date	Number of IMVT Shares Held	Base Market Value of IMVT Shares	Local Market Value of IMVT Shares	Change in IMVT Shares Held	Change in IMVT Base Value	Current Price per IMVT Share Held	Previous Price per IMVT Share Held
2025-11-11 (Tuesday)	113,922	USD 2,607,675	USD 2,607,675	0	USD -54,682	USD 22.89	USD 23.37
2025-11-10 (Monday)	113,922	USD 2,662,357	USD 2,662,357	291	USD 9,073	USD 23.37	USD 23.35
2025-11-07 (Friday)	113,631	USD 2,653,284	USD 2,653,284	0	USD -36,362	USD 23.35	USD 23.67
2025-11-06 (Thursday)	113,631	USD 2,689,646	USD 2,689,646	291	USD 14,822	USD 23.67	USD 23.6
2025-11-05 (Wednesday)	113,340	USD 2,674,824	USD 2,674,824	0	USD -66,871	USD 23.6	USD 24.19
2025-11-04 (Tuesday)	113,340	USD 2,741,695	USD 2,741,695	293	USD 53,437	USD 24.19	USD 23.78
2025-11-03 (Monday)	113,047	USD 2,688,258	USD 2,688,258	0	USD -101,742	USD 23.78	USD 24.68
2025-10-31 (Friday)	113,047	USD 2,790,000	USD 2,790,000	0	USD -15,827	USD 24.68	USD 24.82
2025-10-30 (Thursday)	113,047	USD 2,805,827	USD 2,805,827	1,465	USD 390,077	USD 24.82	USD 21.65
2025-10-29 (Wednesday)	111,582	USD 2,415,750	USD 2,415,750	586	USD -23,942	USD 21.65	USD 21.98
2025-10-28 (Tuesday)	110,996	USD 2,439,692	USD 2,439,692	0	USD 61,048	USD 21.98	USD 21.43
2025-10-27 (Monday)	110,996	USD 2,378,644	USD 2,378,644	0	USD 276,380	USD 21.43	USD 18.94

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of IMVT by Blackrock for IE00BDZVHG35

Show aggregate share trades of IMVT

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-11-10 BUY 291 23.800 21.430 21.667 USD 6,305 19.71
2025-11-06 BUY 291 24.270 23.400 23.487 USD 6,835 19.67
2025-11-04 BUY 293 24.530 23.310 23.432 USD 6,866 19.62
2025-10-30 BUY 1,465 26.170 21.830 22.264 USD 32,617 19.54
2025-10-29 BUY 586 21.650 22.140 22.091 USD 12,945 19.53
2025-10-22 SELL -1,168 18.900 19.420 19.368 USD -22,622 19.52 Profit of 172 on sale
2025-10-20 BUY 584 19.220 19.360 19.346 USD 11,298 19.52
2025-10-17 BUY 1,463 17.510 17.590 17.582 USD 25,722 19.53
2025-10-15 BUY 2,328 17.930 18.065 18.052 USD 42,024 19.54
2025-10-03 BUY 2,016 16.900 17.090 17.071 USD 34,415 19.57
2025-10-02 BUY 288 16.730 16.850 16.838 USD 4,849 19.59
2025-09-30 BUY 576 16.120 16.170 16.165 USD 9,311 19.63
2025-09-26 BUY 576 16.230 16.515 16.486 USD 9,496 19.67
2025-09-25 BUY 576 15.670 16.100 16.057 USD 9,249 19.69
2025-09-18 BUY 298 15.400 15.550 15.535 USD 4,629 19.72
2025-09-17 BUY 897 15.110 15.820 15.749 USD 14,127 19.75
2025-07-17 SELL -594 18.280 18.380 18.370 USD -10,912 19.81 Profit of 857 on sale
2025-07-16 BUY 1,491 17.810 17.920 17.909 USD 26,702 19.83
2025-07-11 SELL -2,344 18.130 18.230 18.220 USD -42,708 19.86 Profit of 3,847 on sale
2025-07-02 BUY 16,115 16.810 17.060 17.035 USD 274,519 19.94
2025-06-25 BUY 586 15.750 16.000 15.975 USD 9,361 20.04
2025-06-20 BUY 2,963 15.800 16.040 16.016 USD 47,455 20.14
2025-06-11 BUY 568 16.150 17.080 16.987 USD 9,649 20.37
2025-06-10 BUY 568 16.740 16.955 16.933 USD 9,618 20.39
2025-06-04 SELL -284 15.340 15.660 15.628 USD -4,438 20.53 Profit of 1,392 on sale
2025-04-23 BUY 283 14.450 15.165 15.093 USD 4,271 22.31
2025-04-10 SELL -2,264 14.790 15.370 15.312 USD -34,666 23.06 Profit of 17,534 on sale
2025-04-08 SELL -283 13.310 15.165 14.980 USD -4,239 23.26 Profit of 2,344 on sale
2025-04-07 SELL -283 14.390 15.290 15.200 USD -4,302 23.37 Profit of 2,311 on sale
2025-04-04 SELL -1,415 14.580 15.670 15.561 USD -22,019 23.47 Profit of 11,190 on sale
2025-04-01 BUY 2,497 15.200 17.090 16.901 USD 42,202 23.65
2025-03-31 SELL -837 17.090 17.810 17.738 USD -14,847 23.73 Profit of 5,018 on sale
2025-03-21 BUY 14,459 19.640 19.750 19.739 USD 285,406 24.13
2025-03-14 SELL -3,696 19.520 19.520 19.520 USD -72,146 24.46 Profit of 18,273 on sale
2025-03-07 SELL -462 20.020 20.030 20.029 USD -9,253 24.83 Profit of 2,220 on sale
2025-03-04 SELL -231 18.490 18.670 18.652 USD -4,309 25.11 Profit of 1,491 on sale
2025-02-25 BUY 462 19.780 20.630 20.545 USD 9,492 25.56
2025-02-19 SELL -231 20.820 21.160 21.126 USD -4,880 25.92 Profit of 1,107 on sale
2025-02-13 BUY 690 19.860 20.040 20.022 USD 13,815 26.36
2025-02-12 BUY 230 19.220 19.570 19.535 USD 4,493 26.51
2025-02-11 BUY 920 19.340 20.185 20.100 USD 18,492 26.66
2024-12-30 SELL -7,741 23.880 24.551 24.484 USD -189,530 28.78 Profit of 33,221 on sale
2024-11-18 SELL -3,765 25.510 27.000 26.851 USD -101,094 29.96 Profit of 11,710 on sale
2024-11-08 SELL -251 30.650 31.260 31.199 USD -7,831 29.96 Loss of -311 on sale
2024-10-21 SELL -251 29.370 29.630 29.604 USD -7,431 0.00 Loss of -7,431 on sale
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-11-10	BUY	291	23.800	21.430	21.667	USD 6,305	19.71
2025-11-06	BUY	291	24.270	23.400	23.487	USD 6,835	19.67
2025-11-04	BUY	293	24.530	23.310	23.432	USD 6,866	19.62
2025-10-30	BUY	1,465	26.170	21.830	22.264	USD 32,617	19.54
2025-10-29	BUY	586	21.650	22.140	22.091	USD 12,945	19.53
2025-10-22	SELL	-1,168	18.900	19.420	19.368	USD -22,622	19.52 Profit of 172 on sale
2025-10-20	BUY	584	19.220	19.360	19.346	USD 11,298	19.52
2025-10-17	BUY	1,463	17.510	17.590	17.582	USD 25,722	19.53
2025-10-15	BUY	2,328	17.930	18.065	18.052	USD 42,024	19.54
2025-10-03	BUY	2,016	16.900	17.090	17.071	USD 34,415	19.57
2025-10-02	BUY	288	16.730	16.850	16.838	USD 4,849	19.59
2025-09-30	BUY	576	16.120	16.170	16.165	USD 9,311	19.63
2025-09-26	BUY	576	16.230	16.515	16.486	USD 9,496	19.67
2025-09-25	BUY	576	15.670	16.100	16.057	USD 9,249	19.69
2025-09-18	BUY	298	15.400	15.550	15.535	USD 4,629	19.72
2025-09-17	BUY	897	15.110	15.820	15.749	USD 14,127	19.75
2025-07-17	SELL	-594	18.280	18.380	18.370	USD -10,912	19.81 Profit of 857 on sale
2025-07-16	BUY	1,491	17.810	17.920	17.909	USD 26,702	19.83
2025-07-11	SELL	-2,344	18.130	18.230	18.220	USD -42,708	19.86 Profit of 3,847 on sale
2025-07-02	BUY	16,115	16.810	17.060	17.035	USD 274,519	19.94
2025-06-25	BUY	586	15.750	16.000	15.975	USD 9,361	20.04
2025-06-20	BUY	2,963	15.800	16.040	16.016	USD 47,455	20.14
2025-06-11	BUY	568	16.150	17.080	16.987	USD 9,649	20.37
2025-06-10	BUY	568	16.740	16.955	16.933	USD 9,618	20.39
2025-06-04	SELL	-284	15.340	15.660	15.628	USD -4,438	20.53 Profit of 1,392 on sale
2025-04-23	BUY	283	14.450	15.165	15.093	USD 4,271	22.31
2025-04-10	SELL	-2,264	14.790	15.370	15.312	USD -34,666	23.06 Profit of 17,534 on sale
2025-04-08	SELL	-283	13.310	15.165	14.980	USD -4,239	23.26 Profit of 2,344 on sale
2025-04-07	SELL	-283	14.390	15.290	15.200	USD -4,302	23.37 Profit of 2,311 on sale
2025-04-04	SELL	-1,415	14.580	15.670	15.561	USD -22,019	23.47 Profit of 11,190 on sale
2025-04-01	BUY	2,497	15.200	17.090	16.901	USD 42,202	23.65
2025-03-31	SELL	-837	17.090	17.810	17.738	USD -14,847	23.73 Profit of 5,018 on sale
2025-03-21	BUY	14,459	19.640	19.750	19.739	USD 285,406	24.13
2025-03-14	SELL	-3,696	19.520	19.520	19.520	USD -72,146	24.46 Profit of 18,273 on sale
2025-03-07	SELL	-462	20.020	20.030	20.029	USD -9,253	24.83 Profit of 2,220 on sale
2025-03-04	SELL	-231	18.490	18.670	18.652	USD -4,309	25.11 Profit of 1,491 on sale
2025-02-25	BUY	462	19.780	20.630	20.545	USD 9,492	25.56
2025-02-19	SELL	-231	20.820	21.160	21.126	USD -4,880	25.92 Profit of 1,107 on sale
2025-02-13	BUY	690	19.860	20.040	20.022	USD 13,815	26.36
2025-02-12	BUY	230	19.220	19.570	19.535	USD 4,493	26.51
2025-02-11	BUY	920	19.340	20.185	20.100	USD 18,492	26.66
2024-12-30	SELL	-7,741	23.880	24.551	24.484	USD -189,530	28.78 Profit of 33,221 on sale
2024-11-18	SELL	-3,765	25.510	27.000	26.851	USD -101,094	29.96 Profit of 11,710 on sale
2024-11-08	SELL	-251	30.650	31.260	31.199	USD -7,831	29.96 Loss of -311 on sale
2024-10-21	SELL	-251	29.370	29.630	29.604	USD -7,431	0.00 Loss of -7,431 on sale

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of IMVT

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	237,771	0	521,187	45.6%
2025-09-18	226,775	0	506,190	44.8%
2025-09-17	318,308	0	572,777	55.6%
2025-09-16	284,018	0	524,501	54.2%
2025-09-15	298,530	184	553,288	54.0%
2025-09-12	266,121	411	919,716	28.9%
2025-09-11	239,307	8,320	608,146	39.4%
2025-09-10	226,067	533	740,817	30.5%
2025-09-09	206,013	0	593,070	34.7%
2025-09-08	386,759	0	554,652	69.7%
2025-09-05	275,617	5,000	968,660	28.5%
2025-09-04	462,842	4,880	766,807	60.4%
2025-09-03	1,074,129	22,370	2,021,541	53.1%
2025-09-02	219,699	0	617,991	35.6%
2025-08-29	104,250	0	282,354	36.9%
2025-08-28	83,203	190	219,044	38.0%
2025-08-27	117,872	143	563,634	20.9%
2025-08-26	86,125	0	351,038	24.5%
2025-08-25	114,242	0	393,226	29.1%
2025-08-22	81,723	0	567,871	14.4%
2025-08-21	86,392	0	519,866	16.6%
2025-08-20	107,531	100	642,292	16.7%
2025-08-19	105,490	0	456,267	23.1%
2025-08-18	105,745	501	404,902	26.1%
2025-08-15	95,384	1,200	1,001,483	9.5%
2025-08-14	106,216	0	467,028	22.7%
2025-08-13	157,418	3,846	443,391	35.5%
2025-08-12	351,306	0	413,333	85.0%
2025-08-11	264,054	0	468,922	56.3%
2025-08-08	166,099	324	243,990	68.1%
2025-08-07	103,572	8	177,672	58.3%
2025-08-06	171,455	66	250,718	68.4%
2025-08-05	174,569	0	295,997	59.0%
2025-08-04	125,814	0	208,570	60.3%
2025-08-01	325,671	223	565,813	57.6%
2025-07-31	182,552	213	394,833	46.2%
2025-07-30	199,331	0	404,854	49.2%
2025-07-29	186,864	6,654	505,167	37.0%
2025-07-28	242,810	16,158	605,008	40.1%
2025-07-25	729,813	11,659	1,679,637	43.5%
2025-07-24	226,015	38,604	388,761	58.1%
2025-07-23	284,309	69,677	444,147	64.0%
2025-07-22	160,560	33,025	259,862	61.8%
2025-07-21	130,773	0	240,834	54.3%
2025-07-18	169,609	0	264,619	64.1%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.

Stock Name / Fund	iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Issuer	Blackrock
ETF Ticker	BTEE(USD) LSE
ETF Ticker	BTEE.L(GBP) LSE